The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
HOME > BUSINESS
BUSINESS
- Eisai to File Halaven for Soft Tissue Sarcomas; PIII Study Results Show Significant Prolongation of OS
February 26, 2015
- Takeda to Acquire Turkish Firm for Up to 14.5 Billion Yen, Earn 13 Branded Generics
February 25, 2015
- Daiichi Sankyo to Shake Up Japan Organization as Olmetec Patent Expiry Nears
February 25, 2015
- Japan’s 6th SGLT-2 Inhibitor Jardiance Hits Market
February 25, 2015
- US FDA Accepts NDA for Lonsurf: Taiho
February 24, 2015
- Takeda, Queen Mary University of London to Collaborate for Novel Drug Discovery in Gastroenterology Field
February 24, 2015
- MHLW OKs Additional Indications for E Keppra, Adempas
February 23, 2015
- Sun Pharma Wins Japan Approval for Cravit Generics, Competition with Daiichi Sankyo Might Arise
February 23, 2015
- J-Pharma Initiates PI Trial of LAT1 Inhibitor
February 23, 2015
- Pfizer Japan Receives Approval for Japan’s 1st Propecia Generic
February 23, 2015
- Bristol-Myers Files Eliquis for Venous Thromboembolism
February 20, 2015
- AnGes MG Changes Collategene Sales Partner in Japan from Daiichi Sankyo to Mitsubishi Tanabe
February 19, 2015
- Daiichi Sankyo Restores Lixiana Supply via Shipping Adjustment Following Demand Surge
February 19, 2015
- Daiwa Securities Unit Sets Up Venture Capital Fund to Support Drug Development
February 19, 2015
- Edoxaban Can Cover 80% of NOAC-Targeted Patients despite Restricted Use: US Commercial Chief
February 18, 2015
- Ono, Dako to Jointly Develop Companion Diagnostic Test for Opdivo
February 18, 2015
- MSD, Sanofi to Copromote RotaTeq, Heptavax in Japan
February 18, 2015
- Takeda to Terminate Asian PIII Study for Motesanib
February 18, 2015
- Nichi-Iko to Exclusively Market Plavix Authorized Generics
February 17, 2015
- Lenvatinib Obtains World’s 1st Approval in US: Eisai
February 17, 2015
ページ
PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…